Triall Insights. According to the IQVIA Institute, US venture capital deal value in biopharma reached $42B in 2022.
16 May 2023, 09:48
Triall Insights š
According to the IQVIA Institute, US venture capital deal value in biopharma reached $42B in 2022.
Deal activity and investment flows in the US accelerated in the preceding 3 years as interest in Life Sciences intensified, with more than 2,000 deals occurring across 2022.
Source: iqvia.com/insights/the-iqvia-institute/reports/global-trends-in-r-and-d-2023
ā”ļø Trade $TRL at bit.ly/tradeTRL
š£ Help spread the news on Twitter:
#blockchainforhealth #TRL
Same news in other sources
116 May 2023, 09:48
Triall Insights š
According to the IQVIA Institute, US venture capital deal value in biopharma reached $42B in 2022.
Deal activity and investment flows in the US accelerated in the preceding 3 years as interest in Life Sciences intensified, with more than 2,000 deals occurring across 2022.
Source: iqvia.com/insights/the-iqvia-institute/reports/global-trends-in-r-and-d-2023
ā”ļø Trade $TRL at bit.ly/tradeTRL
š£ Help spread the news on Twitter:
#blockchainforhealth #TRL
Triall Insights. According to the IQVIA Institute, US venture capital deal value in biopharma reached $42B in 2022.
Triall Insights š
According to the IQVIA Institute, US venture capital deal value in biopharma reached $42B in 2022.
Deal activity and investment flows in the US accelerated in the preceding 3 years as interest in Life Sciences intensified, with more than 2,000 deals occurring across 2022.
Source: iqvia.com/insights/the-iqvia-institute/reports/global-trends-in-r-and-d-2023
ā”ļø Trade $TRL at bit.ly/tradeTRL
š£ Help spread the news on Twitter:
https://twitter.com/triallofficial/status/1658408678045745152?s=20
#blockchainforhealth #TRL